Quick answer: for most people, how to get Wegovy for free comes down to three routes: a state Medicaid program that covers obesity drugs (13 states as of January 2026), a clinical trial, or rare cases of full insurance coverage.[2] Novo Nordisk’s Patient Assistance Program does not list Wegovy.[1] The closest low-cost options are the $50 Medicare GLP-1 Bridge, the $25 copay card for commercial plans and NovoCare’s $199 to $349 self-pay prices.[5][6][7]
Prices and program terms checked October 2026. They change often; confirm with the manufacturer or your plan.
Wegovy is the brand of semaglutide approved for weight management, heart risk reduction and MASH liver disease. Its list price is $1,349.02 per package.[11] Most people who pay little for it do so through insurance or a government program, so the first step is to know which of these you qualify for.
Can you get Wegovy free from Novo Nordisk?
Not usually. Novo Nordisk’s Patient Assistance Program (PAP) gives free medicine to some uninsured people and Medicare enrollees with low incomes. However, the program sits in NovoCare’s diabetes section, and its page names Ozempic with a household income limit of 200% of the federal poverty level. Wegovy is not mentioned.[1] People with private or commercial insurance cannot use the PAP at all.[1]
If you have type 2 diabetes, your clinician may consider Ozempic, which contains the same drug and is covered by the PAP for eligible people. See our guide to how to qualify for Ozempic for what that requires.
Medicaid: the main route to free or near-free Wegovy
Medicaid is the only large program where Wegovy can cost little or nothing. Coverage depends on your state:
- 13 states covered GLP-1s for obesity in their fee-for-service programs as of January 2026, according to KFF.[2]
- 4 states dropped coverage after October 2025: California, New Hampshire, Pennsylvania and South Carolina. North Carolina dropped coverage in October 2025 and restored it in December 2025.[2]
- Costs are low where it is covered, because federal law limits Medicaid cost sharing to nominal amounts.[3]
States can also opt in to CMS’s BALANCE model, which lets Medicaid programs cover GLP-1s for weight loss at prices CMS negotiates with manufacturers. States can join on a rolling basis from May 2026 through January 1, 2027.[4] Ask your state Medicaid agency or managed care plan whether it participates. For more detail, see does Medicaid cover Ozempic.
Medicare: $50 a month, not free
Medicare drug plans have long been barred from covering drugs used only for weight loss. Since July 1, 2026, the temporary Medicare GLP-1 Bridge lets eligible Part D enrollees get Wegovy (pen or pill) for weight loss for a $50 copay per month, through December 31, 2027.[5]
To qualify, you must be 18 or older and meet one of these:[5]
- BMI of 35 or higher
- BMI of 30 or higher plus heart failure with preserved ejection fraction, uncontrolled high blood pressure or stage 3a+ kidney disease
- BMI of 27 or higher plus prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease
The $50 cannot be reduced by Extra Help, so this route is low-cost rather than free.[5] Wegovy prescribed to lower heart attack and stroke risk is handled by your regular Part D plan instead. Our guide to Medicare coverage of Ozempic explains how the two paths differ.
Commercial insurance and the $25 copay card
If your employer plan covers Wegovy, Novo Nordisk’s savings offer can lower your copay to as little as $25, with a maximum saving of $100 per one-month fill ($300 per three-month fill).[6] People in Medicare, Medicaid, TRICARE or VA programs cannot use the copay offer.[6]
The catch is that many plans do not cover weight-loss drugs, and those that do usually require prior authorization. See does insurance cover Wegovy and our Wegovy prior authorization guide for how to check and how to improve your odds.
Clinical trials: free study drug, with trade-offs
Research studies of semaglutide and newer obesity drugs usually supply the study medicine at no charge. You can search recruiting studies on ClinicalTrials.gov by drug and location.[9]
Know the trade-offs before you sign up:
- You may get placebo. In the STEP 1 trial, people on placebo lost 2.4% of body weight over 68 weeks, compared with 14.9% on semaglutide 2.4 mg.[8]
- Supply ends with the study. Weight often returns after semaglutide stops, so plan ahead for what happens next.
- Eligibility is strict. Trials set BMI, age and health criteria and require regular visits.
The cheapest paid options
If none of the free routes fit, these are the lowest prices Novo Nordisk publishes for people paying cash:[7]
| Option | Price per month | Notes |
|---|---|---|
| Wegovy pill 1.5 mg | $149 | One 30-tablet bottle |
| Wegovy pill 4 mg | $199 | |
| Wegovy pill 9 mg or 25 mg | $299 | |
| Wegovy pen, first two fills (new patients) | $199 | 0.25 mg or 0.5 mg, through Dec 31, 2026 |
| Wegovy pen 0.25 mg to 2.4 mg | $349 | One box of 4 pens |
| Wegovy HD pen 7.2 mg | $399 | |
| With commercial coverage + savings offer | As little as $25 | Up to $100 off per month[6] |
| Medicare GLP-1 Bridge | $50 | Eligible Part D enrollees[5] |
Cash payments do not count toward your insurance deductible or out-of-pocket limit.[11] For a fuller look at paying out of pocket, see how to get semaglutide without insurance.
Watch out for “free Wegovy” offers
Wegovy is made only by Novo Nordisk and needs a prescription. FDA has warned about unapproved, counterfeit and compounded GLP-1 products marketed online, and it has received reports of harm linked to them.[10]
A step-by-step plan
- Check public coverage first. If your income is low, apply for Medicaid and ask whether your state covers obesity drugs.
- If you have Medicare, ask your prescriber whether you meet the GLP-1 Bridge criteria.
- If you have job-based insurance, look up Wegovy in your plan’s formulary and ask about prior authorization, then activate the savings offer.
- Search for clinical trials if you are open to a research study.
- Compare self-pay prices for the pill and the pen with your prescriber, who sets the dose.
